Specifically, treatment with SGLT2 inhibitors was associated with a 20% relative reduction in all-cause mortality (RR = 0.80; 95%CI: 0.75-0.86) and a 24% relative reduction in HF-related rehospitalizations (RR = 0.76; 95% CI: 0.71-0.81). The gene discussed is SLC5A2; the disease is hydrops fetalis.